SCHEMBL14901498

SCHEMBL14901498

OCC(O)COc1ccc(Oc2ccc(OCC(O)CCl)cc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.69
TSHR P16473 2/20 0.46
MAPK1 P28482 1/20 0.46
MAPT P10636 3/20 0.44
HTT P42858 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
LMNA P02545 2/20 0.42
POLB P06746 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CYP1A2 P05177 4/20 0.41
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 1/20 0.41
AGTR1 P30556 1/20 0.41
ATM Q13315 1/20 0.40
HIF1A Q16665 1/20 0.40
CYP2C19 P33261 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CYP2D6 P10635 1/20 0.39
FGFR1 P11362 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12517404 0.93 AR (0.58) ARTSHRMAPK1MAPTHTT
SCHEMBL5010945 0.91 AR (0.56) ARTSHRMAPK1MAPTHTT
SCHEMBL14901501 0.89 AR (0.69) ARTSHRMAPK1MAPTHTT
SCHEMBL12516208 0.88 AR (0.56) ARTSHRMAPK1MAPTHTT
SCHEMBL7090393 0.87 AR (0.64) ARTSHRMAPK1MAPTHTT
SCHEMBL25158746 0.86 AR (0.66) ARTSHRMAPK1MAPTHTT
SCHEMBL30356354 0.86 AR (0.66) ARTSHRMAPK1MAPTHTT
SCHEMBL30356266 0.86 AR (0.66) ARTSHRMAPK1MAPTHTT
SCHEMBL1496811 0.86 MAPT (0.56) ARTSHRMAPTHTTSMN1; SMN2
SCHEMBL14901493 0.85 AR (0.64) ARTSHRMAPK1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130109758-A1 BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2013-05-02 US disclosed
US-20130109758-A1 BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2013-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109758-A1 BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE SHBG, KLK3, HSD17B11 AR 4/4885TSHR 2717/4885MAPK1 3831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.